

THINK ERCHONIA 1ST

1. The 1st low level laser given 510 (k) market clearance for any indication by the FDA January 2002.
2. The 1st red laser given market clearance by the FDA. FDA Market Clearance was based on 2 level (1) double-blind, randomized, multi-site and placebo controlled clinical trials on chronic neck and shoulder pain.
3. The 1st and only 510 (k) for liposuction in September 2004. Based on research from a 700 patient pilot study and a level (1) double-blind, randomized, multi-site placebo controlled clinical trial.
4. The 1st violet laser given 510 (k) by the FDA in May 2005 for Acne.
5. The 1st laser FDA 510 (k) for Breast Augmentation in August 2008. Based on research from a 100 patient level (1) double-blind, randomized, multi-site and placebo controlled clinical trial.
6. The 1st company that created the fat reducing laser category (OLI) with the FDA in August 2010.
7. The 1st low level laser scanner given 510 (k) market clearance by the FDA in August 2010.
8. The 1st non-invasive laser device given 510 (k) market clearance in August 2010.
9. The 1st device given 510 (k) in August 2010 for non-invasive circumference reduction of the waist, hips and thighs. FDA Market Clearance based on a level (1) 67 patient double-blind, randomized, multi-site and placebo controlled clinical trial.
10. The 1st device given 510 (k) May 2012 for non-invasive circumference reduction of the arms. Market Clearance based on a 66 patient level (1) double-blind, randomized, multi-site and placebo controlled clinical trial 2012.
11. The 1st green laser given 510 (k) market clearance by the FDA 2013.
12. The 1st green laser given 510 (k) January 2013 for circumference reduction based on a 70 patient level (1) double-blind, randomized multi-site and placebo controlled clinical trial.
13. The 1st laser given 510 (k) market clearance in April 2014 for chronic heel pain from plantar fasciitis. Double blind, randomized and multi-site and placebo controlled clinical trial with 1 year follow up.
14. The 1st laser given 510 (k) market clearance in October 2014 for non-invasive circumference reduction of the waist, hips and upper abdomen for BMI Index between 30 and 40.
15. The 1st laser given 510 (k) market clearance in January 2015 for Over the Counter (OTC) circumference reduction of the waist, hips and thighs.
16. 1st company to get FDA 510 (k) market clearance for 2 different protocols with 1 device. (1x week treatment per week or 3x treatments a week).
17. 1st and only non-thermal FDA 510 (k) market cleared laser device to target onychomycosis.
18. 1st and only non-thermal FDA 510 (k) market cleared laser device to receive overall body circumference reduction for a non-invasive fat loss laser.

Erchonia is 1st Based on Level (1) Research

ADDITIONAL RESEARCH:

At Erchonia we are always looking at new applications implementing our patented lasers. Each indication has a device that is manufactured for that specific indication.

All of our level (1) clinical trials have gone through the FDA pre-IDE process and have preset clinical outcomes based on pilot research to ensure our customers can be assured that the laser they are purchasing for each specific indication has been proven safe and effective by the US FDA.

ADDRESS

650 Atlantis Rd.
Melbourne, FL 32904

TELEPHONE

(321) 473-1251
(321) 473-1608 Fax
(888) 242-0571 Toll Free

WEB

info@erchonia.com
www.erchonia.com

We are always working on over a dozen research projects at any time trying to further the science of LLLT (3LT®). Below is a list of mechanisms we have looked at and proven. Please understand due to FDA regulations, we only advertise what we believe the FDA will allow us to market.

MECHANISMS:

1. Transitory pore on fat cells SEM and TEM - comparison between control and treated (2002-2008). Well published. -*Rodrigo Neira, MD*
2. MRI study proving fat emulsification and depth of penetration - comparison between control and treated (2001). -*Rodrigo Neira, MD*
3. SEM, TEM and punch biopsy of fat live tissue comparison between control and treated (2003). -*Susan Limm, MD and Arturo Ramirez, MD*
4. Joules calculation for wound healing (2003). -*Farouk Al-Watban, M Sc, PhD*
5. Comparison between pulsed and constant wave (CW) (2004). - *Farouk Al-Watban, M Sc, PhD*
6. U.C.S.D Flap Study and Necrosis - animal model comparison between controls and treated (2007) -*Mayer Tennehaus, MD*
7. U.C.S.D. TNF alpha - animal model comparison between control and treated (2007). -*Mayer Tennehaus, MD*
8. U.C.S.D. Apoptosis on 2nd degree burns - animal model compared between controls and treated (2007). -*Mayer Tennehaus, MD*
9. Oklahoma State University - animal model for wound healing (equine) hyperplastic epithelium comparison between controls and treated (2012). -*Hank Jann, DVM*

ADDRESS

650 Atlantis Rd.
Melbourne, FL 32904

TELEPHONE

(321) 473-1251
(321) 473-1608 Fax
(888) 242-0571 Toll Free

WEB

info@erchonia.com
www.erchonia.com

